University of Wisconsin–Madison

Ricke lab discovers a novel mechanism and possible treatment for castration resistant prostate cancer

Dr. William Ricke’s laboratory has discovered a potential method to treat castration resistant prostate cancer (CRPC), by targeting a novel molecular mechanism involving RNA-binding protein.  Drs. Ricke, Vellky, and colleagues have described DDX3 (DEAD-box helicase 3 X-linked) as a key repressor of AR protein translation that may be targetable for sensitizing AR low/negative CRPC subtypes to AR-directed therapies.

“The emergence of AR low/negative castration-resistant prostate cancer has led to grim prognoses for men around the world,” said Ricke. “We hope this discovery is a significant step to providing effective therapeutics for those facing castration resistant diseases including prostate cancer and Benign Prostatic Hyperplasia.”

See full publication here:

Leave a Reply

Your email address will not be published. Required fields are marked *